View Author
patient study treatment health group month therapy myeloma result difference netherland women bortezomib hospital trial practice table quality dutch cancer tumor country analysis thalidomide novel agents model agent review vkorc novel antenatal care university signi –effectivenes effectiveness disease stroke genotype variable outcome factor effect evaluation population lenalidomide cyp 2c coumarin cost –effectiveness fi rst month range phase oxaliplatin dexamethasone acenocoumarol anticoagulation response antenatal cam-icu dasatinib pregnancy event anticoagulant unit costs analyses prevention number pressure value resource regimen center delirium percentage signi ficantly assessment vkorc 1 blood atrial fibrillation score estimate
10 Most Recent Publications
|
Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents
(Article)
Gaultney, J.G. Franken, M. Tan, S.S. Orlewska, E. Huijgens, P.C. Sonneveld, P. Uyl-de Groot, C.A. |
2013-02-01
|
|
Long-term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users
(Article)
Verhoef, T.I. Orlewska, E. Hegazy, H. Boer, A. de Maitland-van der Zee, A-H. |
2012-12-01
|
|
The effect of omeprazole and esomeprazole on the maintenance dose of phenprocoumon
(Letter To Editor)
Verhoef, T.I. Zuurhout, M.J.L. Schie, R.M.F. van Orlewska, E. Meer, F.J.M. van der Cessie, S. le Schalekamp, T. Boer, A. de Maitland-van der Zee, A-H. |
2012-12-01
|
|
Explaining length of stay variation of episodes of care in the Netherlands
(Article)
Tan, S.S. Hakkaart-van Roijen, L. Ineveld, B.M. van Orlewska, E. |
2012-10-22
|
|
Cost-effectiveness of pharmacogenetics in anticoagulation: International differences in healthcare systems and costs
(Article)
Verhoef, T.I. Orlewska, E. Manolopoulos, V.G. Pirmohamed, M. Siebert, U. Stingl, J.C. Wadelius, M. Boer, A. de Maitland-van der Zee, A-H. Schie, R.M.F. van Bayat, S. Daly, A.K. Geitona, M. Haschke-Becher, E. Hughes. D.A. Kamali, F. Levin, L.A. |
2012-09-01
|
|
Novel anticancer agents for multiple myeloma: A review of the evidence for their therapeutic and economic value
(Article)
Gaultney, J.G. Orlewska, E. Sonneveld, P. Uyl-de Groot, C.A. |
2012-06-01
|
|
Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users
(Article)
Verhoef, T.I. Orlewska, E. Visser, L.E. Maitland-van der Zee, A-H. Buikema, M.M. Schalekamp, T. Meer, F.J.M. van der Cessie, S. le Wessels, J.A.M. Schie, R.M.F. van Boer, A. de Teichert, M. |
2012-04-01
|
|
Adjuvant chemotherapy in stage III colon cancer: Guideline implementation, patterns of use and outcomes in daily practice in the Netherlands
(Article)
Gils, C.W.M. van Koopman, M. Mol, L. Orlewska, E. Uyl-de Groot, C.A. Punt, C.J.A. |
2012-01-01
|
|
A new test of the construct validity of the CarerQol instrument: Measuring the impact of informal care giving
(Article)
Hoefman, R.J. Exel, N.J.A. van Looren De Jong, S. Orlewska, E. Brouwer, W.B.F. |
2011-08-01
|
|
Critical review of economic evaluations in multiple myeloma: An overview of the economic evidence and quality of the methodology
(Article)
Gaultney, J.G. Orlewska, E. Sonneveld, P. Uyl-de Groot, C.A. |
2011-07-01
|
